Jarrod John Sandow

Jarrod John Sandow

Auto-generated profile, based on publicly available information

Jarrod John Sandow

Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHui Chin
Hui Chin
MLMark X. Li
Mark X. Li
ITIris K. L. Tan
Iris K. L. Tan
RNRobert L. Ninnis
Robert L. Ninnis
BRBoris Reljic
Boris Reljic
GDGrant Dewson
Grant Dewson
Intrinsic apoptosis is critical to prevent tumor formation and is engaged by many anti-cancer agents to eliminate tumor cells. BAX and BAK, the two essential mediators of apoptosis, are thought to be regulated through similar mechanisms and act redundantly to drive apoptotic cell death. From an unbiased genome-wide CRISPR/Cas9 screen, we identified VDAC2 (voltage-dependent anion channel 2) as important for BAX, but not BAK, to function. Genetic deletion of VDAC2 abrogated the association of BAX and BAK with mitochondrial complexes containing VDAC1, VDAC2, and VDAC3, but only inhibited BAX apoptotic function. Deleting VDAC2 phenocopied the loss of BAX in impairing both the killing of tumor cells by anti-cancer agents and the ability to suppress tumor formation. Together, our studies show that efficient BAX-mediated apoptosis depends on VDAC2, and reveal a striking difference in how BAX and BAK are functionally impacted by their interactions with VDAC2.

1 May 2021 in Molecular Cell
Verified
Journal Article
Closed access
SHSimon J Hogg
Simon J Hogg
OMOlga Motorna
Olga Motorna
LCLeonie A Cluse
Leonie A Cluse
TJTimothy M Johanson
Timothy M Johanson
HCHannah D Coughlan
Hannah D Coughlan
RJRicky W Johnstone
Ricky W Johnstone

1 March 2015 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
NLNajoua Lalaoui
Najoua Lalaoui
LLLisa M. Lindqvist
Lisa M. Lindqvist
JSJarrod J. Sandow
Jarrod J. Sandow
PEPaul Ekert
Paul Ekert

14 May 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ELemily lelliott
emily lelliott
IKIsabella Y. Kong
Isabella Y. Kong
MZMagnus Zethoven
Magnus Zethoven
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
LMLuciano G. Martelotto
Luciano G. Martelotto
SVStephin J. Vervoort
Stephin J. Vervoort
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor–positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical success of these inhibitors is largely attributed to well-defined tumor-intrinsic cytostatic mechanisms, whereas their emerging role as immunomodulatory agents is less understood. Using integrated epigenomic, transcriptomic, and proteomic analyses, we demonstrated a novel action of CDK4/6 inhibitors in promoting the phenotypic and functional acquisition of immunologic T-cell memory. Short-term priming with a CDK4/6 inhibitor promoted long-term endogenous antitumor T-cell immunity in mice, enhanced the persistence and therapeutic efficacy of chimeric antigen receptor T cells, and induced a retinoblastoma-dependent T-cell phenotype supportive of favorable responses to immune checkpoint blockade in patients with melanoma. Together, these mechanistic insights significantly broaden the prospective utility of CDK4/6 inhibitors as clinical tools to boost antitumor T-cell immunity. Significance: Immunologic memory is critical for sustained antitumor immunity. Our discovery that CDK4/6 inhibitors drive T-cell memory fate commitment sheds new light on their clinical activity, which is essential for the design of clinical trial protocols incorporating these agents, particularly in combination with immunotherapy, for the treatment of cancer. This article is highlighted in the In This Issue feature, p. 2355

18 January 2021 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
YMYanxiang Meng
Yanxiang Meng
JSJarrod J. Sandow
Jarrod J. Sandow
PCPeter E. Czabotar
Peter E. Czabotar
JMJames M. Murphy
James M. Murphy

22 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YMYanxiang Meng
Yanxiang Meng
KDKatherine A. Davies
Katherine A. Davies
CFCheree Fitzgibbon
Cheree Fitzgibbon
SYSamuel N. Young
Samuel N. Young
SGSarah E. Garnish
Sarah E. Garnish
JMJames M. Murphy
James M. Murphy
The ancestral origins of the lytic cell death mode, necroptosis, lie in host defense. However, the dysregulation of necroptosis in inflammatory diseases has led to widespread interest in targeting the pathway therapeutically. This mode of cell death is executed by the terminal effector, the MLKL pseudokinase, which is licensed to kill following phosphorylation by its upstream regulator, RIPK3 kinase. The precise molecular details underlying MLKL activation are still emerging and, intriguingly, appear to mechanistically-diverge between species. Here, we report the structure of the human RIPK3 kinase domain alone and in complex with the MLKL pseudokinase. These structures reveal how human RIPK3 structurally differs from its mouse counterpart, and how human RIPK3 maintains MLKL in an inactive conformation prior to induction of necroptosis. Residues within the RIPK3:MLKL C-lobe interface are crucial to complex assembly and necroptotic signaling in human cells, thereby rationalizing the strict species specificity governing RIPK3 activation of MLKL.